Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1612 1613 1624 1715
This examiner grants 52% of resolved cases
Andrew S. Rosenthal is an examiner in Art Unit 1612 of Tech Center 1700. The examiner has 668 resolved cases and an allowance rate of 51.8 percent. This rate indicates a more challenging environment for applicants, with roughly half of the cases reaching allowance. The 668 resolved cases provide a substantial dataset that highlights the examiner's rigorous approach to patentability and the need for strong, well-supported applications to achieve a successful outcome.
The interview lift is 38.7 percent, which is a very strong positive indicator. This suggests that interviews are a critical tool for overcoming rejections and significantly improving the chances of a successful outcome with this examiner. The 38.7 percent lift is a clear signal that the examiner is highly responsive to the interactive nature of oral advocacy. Practitioners should prioritize scheduling an interview as soon as a rejection is received to address the examiner's concerns directly and effectively.
The median days to allowance is 1106. This timeline offers a benchmark for the duration of the examination process, allowing applicants to plan for a multi-year prosecution cycle. The 1106-day median is an essential figure for managing the expectations of inventors and corporate leadership. It provides a realistic view of the time commitment required to navigate the examination process and helps in the long-term planning of intellectual property assets.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18939761 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING AMINOPYRIMIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, OR SOLVATE THEREOF | Non-Final OA | Janssen Biotech, Inc. |
| 18911411 | ORAL CARE COMPOSITIONS COMPRISING DICARBOXYLIC ACID | Non-Final OA | The Procter & Gamble Company |
| 17783235 | HAIR STYLING COMPOSITION CONTAINING DISACCHARIDES | Final Rejection | Henkel AG & Co. KGaA |
| 17762674 | METHOD FOR DYEING KERATINOUS MATERIAL BY MEANS OF A PREMIX OF AMINOSILICONE AND A CHROMOPHORIC COMPOUND | Final Rejection | Henkel AG & Co. KGaA |
| 18444413 | INJECTABLE SLURRIES AND METHODS OF MANUFACTURING AND USING THE SAME | Non-Final OA | The General Hospital Corporation |
| 18802089 | IMMUNOSUPPRESSANT FORMULATIONS | Final Rejection | Novartis AG |
| 18723263 | COSMETIC COMPOSITION COMPRISING A POLYHYDROXYALKANOATE COPOLYMER BEARING A(N) (UN)SATURATED HYDROCARBON-BASED CHAIN AND A NATURAL RESIN | Non-Final OA | L'OREAL |
| 18626294 | COMPOSITIONS AND METHODS FOR ALTERING THE COLOR OF HAIR | Non-Final OA | L'Oreal |
| 15993759 | NON-SULFATE CONCENTRATED RINSE-OFF CLEANSING COMPOSITION | Final Rejection | L'OREAL |
| 18357810 | MULTIFUNCTIONAL pO2/pH-SENSITIVE THERANOSTIC LIPOSOME NANOCARRIERS AND METHODS OF USING SAME | Final Rejection | YALE UNIVERSITY |
| 18865623 | ANTIPERSPIRANT COMPOSITION | Non-Final OA | Conopco, Inc., d/b/a UNILEVER |
| 18699471 | AGENT FOR PREVENTING, TREATING, OR IMPROVING INFLAMMATORY SKIN DISEASE | Final Rejection | KAO CORPORATION |
| 18067164 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | Non-Final OA | Firmenich SA |
| 18883199 | ANTI-MICROBIAL IMPLANT COATING | Non-Final OA | Waldemar Link GmbH & Co. KG |
| 18689718 | HYDROPHOBIC AND HYDROPHILIC MODIFIED MALEATED NATURAL OILS AND COMPOSITIONS THEREOF | Non-Final OA | ISP Investments LLC |
| 18640764 | COSMETIC ESTER COMPOSITION | Non-Final OA | PATECH FINE CHEMICALS CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy